<DOC>
	<DOCNO>NCT01790308</DOCNO>
	<brief_summary>The purpose study investigate evaluate effect liraglutide combine short-term continuous subcutaneous insulin infusion ( CSII ) long-term glycemic control β-cell function newly diagnose type 2 diabetic patient .</brief_summary>
	<brief_title>Effect Liraglutide Combined With Short-term CSII Long-term Glycemic Remission β Cell Function</brief_title>
	<detailed_description>The purpose study investigate evaluate effect liraglutide combine short-term continuous subcutaneous insulin infusion ( CSII ) ( 1.CSII alone ; 2.liraglutide combine CSII ) long-term glycemic control β-cell function newly diagnose type 2 diabetic patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>newly diagnose type 2 diabetes fast blood glucose ( FBG ) level range 7.016.7mmol/L body mass index ( BMI ) range 2135kg/m2 antihypercaemic antihyperlipidemic medicationnaive patient severe acute chronic diabetic complication renal dysfunction , blood creatinine &gt; 150umol/L blood aminotransferase level rise ( 2 time upper normal limit ALT ) severe cardiac disease include congestive cardiac failure , unstable angina myocardial infarct 12 month chronic acute pancreatic disease severe systemic disease malignant tumor female patient incline pregnant treated corticosteriod , immunosuppressing drug cytotoxic drug poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>